FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078259729> ?p ?o ?g. }

• W2078259729 endingPage "838" @default.
• W2078259729 startingPage "829" @default.
• W2078259729 abstract "1 The role of nitric oxide (NO) derived from constitutive and inducible nitric oxide synthase (cNOS and iNOS) and its relationship to oxygen-derived free radicals and prostaglandins (PG) was investigated in a carrageenan-induced model of acute hindpaw inflammation. 2 The intraplantar injection of carrageenan elicited an inflammatory response that was characterized by a time-dependent increase in paw oedema, neutrophil infiltration, and increased levels of nitrite/nitrate (NO2-/NO3-) and prostaglandin E2(PGE2) in the paw exudate. 3 Paw oedema was maximal by 6 h and remained elevated for 10 h following carrageenan administration. The non-selective cNOS/iNOS inhibitors, NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-NAME) given intravenously (30-300 mg kg-1) 1 h before or after carrageenan administration, inhibited paw oedema at all time points. 4 The selective iNOS inhibitors, N-iminoethyl-L-lysine (L-NIL) or aminoguanidine (AG), failed to inhibit carrageenan-induced paw oedema during the first 4 h following carrageenan administration, but inhibited paw oedema at subsequent time points (from 5-10 h). iNOS mRNA was detected between 3 to 10 h following carrageenan administration using ribonuclease protection assays. iNOS protein was first detected 6 h and was maximal 10 h following carrageenan administration as shown by Western blot analysis. Administration of the iNOS inhibitors 5 h after carrageenan (a time point where iNOS was expressed) inhibited paw oedema at all subsequent time points. Infiltrating neutrophils were not the source of iNOS since pretreatment with colchicine (2 mg kg-1) suppressed neutrophil infiltration, but did not inhibit the iNOS mRNA expression or the elevated NO2-/NO3- levels in the paw exudate. 5 Inhibition of paw oedema by the NOS inhibitors was associated with attenuation of both the NO2-/NO3- and PGE2 levels in the paw exudate. These inhibitors also reduced the neutrophil infiltration at the site of inflammation. 6 Recombinant human Cu/Zn superoxide dismutase coupled to polyethyleneglycol (PEGrhSOD; 12 x 10(3) u kg-1), administered intravenously either 30 min prior to or 1 h after carrageenan injection, inhibited paw oedema and neutrophil infiltration, but had no effect on NO2-/NO3- or PGE2 production in the paw exudate. The administration of catalase (40 x 10(3) u kg-1), given intraperitoneally 30 min before carrageenan administration, had no effect on paw oedema. Treatment with desferrioxamine (300 mg kg-1), given subcutaneously 1 h before carrageenan, inhibited paw oedema during the first 2 h after carrageenan administration, but not at later times. 7 These results suggest that the NO produced by cNOS is involved in the development of inflammation at early time points following carrageenan administration and that NO produced by iNOS is involved in the maintenance of the inflammatory response at later time points. The potential interactions of NO with superoxide anion and PG is discussed." @default.
• W2078259729 created "2016-06-24" @default.
• W2078259729 creator A5001446657 @default.
• W2078259729 creator A5009768215 @default.
• W2078259729 creator A5026611599 @default.
• W2078259729 creator A5046619134 @default.
• W2078259729 creator A5047789279 @default.
• W2078259729 creator A5073174329 @default.
• W2078259729 creator A5076533281 @default.
• W2078259729 date "1996-06-01" @default.
• W2078259729 modified "2023-10-15" @default.
• W2078259729 title "Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation" @default.
• W2078259729 cites W1489860413 @default.
• W2078259729 cites W1592252967 @default.
• W2078259729 cites W1929009802 @default.
• W2078259729 cites W1965778328 @default.
• W2078259729 cites W1967245379 @default.
• W2078259729 cites W1967315269 @default.
• W2078259729 cites W1968036022 @default.
• W2078259729 cites W1968988918 @default.
• W2078259729 cites W1980528903 @default.
• W2078259729 cites W1986917247 @default.
• W2078259729 cites W1990725138 @default.
• W2078259729 cites W1996462445 @default.
• W2078259729 cites W1997296008 @default.
• W2078259729 cites W1998223853 @default.
• W2078259729 cites W2002069556 @default.
• W2078259729 cites W2018697129 @default.
• W2078259729 cites W2018789478 @default.
• W2078259729 cites W2020358486 @default.
• W2078259729 cites W2024191096 @default.
• W2078259729 cites W2036800888 @default.
• W2078259729 cites W2037597903 @default.
• W2078259729 cites W2040486986 @default.
• W2078259729 cites W2043500156 @default.
• W2078259729 cites W2045846314 @default.
• W2078259729 cites W2049466874 @default.
• W2078259729 cites W2053747754 @default.
• W2078259729 cites W2058137293 @default.
• W2078259729 cites W2071248941 @default.
• W2078259729 cites W2076353960 @default.
• W2078259729 cites W2077249375 @default.
• W2078259729 cites W2083748640 @default.
• W2078259729 cites W2089747387 @default.
• W2078259729 cites W2092763906 @default.
• W2078259729 cites W220113049 @default.
• W2078259729 cites W2261454648 @default.
• W2078259729 cites W2313326603 @default.
• W2078259729 cites W2410075643 @default.
• W2078259729 doi "https://doi.org/10.1111/j.1476-5381.1996.tb15475.x" @default.
• W2078259729 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1909531" @default.
• W2078259729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8799551" @default.
• W2078259729 hasPublicationYear "1996" @default.
• W2078259729 type Work @default.
• W2078259729 sameAs 2078259729 @default.
• W2078259729 citedByCount "618" @default.
• W2078259729 countsByYear W20782597292012 @default.
• W2078259729 countsByYear W20782597292013 @default.
• W2078259729 countsByYear W20782597292014 @default.
• W2078259729 countsByYear W20782597292015 @default.
• W2078259729 countsByYear W20782597292016 @default.
• W2078259729 countsByYear W20782597292017 @default.
• W2078259729 countsByYear W20782597292018 @default.
• W2078259729 countsByYear W20782597292019 @default.
• W2078259729 countsByYear W20782597292020 @default.
• W2078259729 countsByYear W20782597292021 @default.
• W2078259729 countsByYear W20782597292022 @default.
• W2078259729 countsByYear W20782597292023 @default.
• W2078259729 crossrefType "journal-article" @default.
• W2078259729 hasAuthorship W2078259729A5001446657 @default.
• W2078259729 hasAuthorship W2078259729A5009768215 @default.
• W2078259729 hasAuthorship W2078259729A5026611599 @default.
• W2078259729 hasAuthorship W2078259729A5046619134 @default.
• W2078259729 hasAuthorship W2078259729A5047789279 @default.
• W2078259729 hasAuthorship W2078259729A5073174329 @default.
• W2078259729 hasAuthorship W2078259729A5076533281 @default.
• W2078259729 hasBestOaLocation W20782597291 @default.
• W2078259729 hasConcept C178790620 @default.
• W2078259729 hasConcept C185592680 @default.
• W2078259729 hasConcept C203014093 @default.
• W2078259729 hasConcept C2776179834 @default.
• W2078259729 hasConcept C2776384668 @default.
• W2078259729 hasConcept C2776914184 @default.
• W2078259729 hasConcept C2777468819 @default.
• W2078259729 hasConcept C2777622882 @default.
• W2078259729 hasConcept C2781227287 @default.
• W2078259729 hasConcept C2908937200 @default.
• W2078259729 hasConcept C515207424 @default.
• W2078259729 hasConcept C519581460 @default.
• W2078259729 hasConcept C55493867 @default.
• W2078259729 hasConcept C71924100 @default.
• W2078259729 hasConcept C98274493 @default.
• W2078259729 hasConceptScore W2078259729C178790620 @default.
• W2078259729 hasConceptScore W2078259729C185592680 @default.
• W2078259729 hasConceptScore W2078259729C203014093 @default.
• W2078259729 hasConceptScore W2078259729C2776179834 @default.
• W2078259729 hasConceptScore W2078259729C2776384668 @default.
• W2078259729 hasConceptScore W2078259729C2776914184 @default.

• next